These data suggest that PTP1B inhibition might represent a novel therapeutic avenue for the treatment of diabetes associated endothelial dysfunction and might prevent diabetic macrovascular complications such as atherosclerosis and coronary heart disease. This evidence concerns the gene PTPN1 and coronary artery disorder.